Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($13.43), $13.09 worse than the analyst estimate of ($0.34). Revenue for the quarter came in at $159.9 million versus the consensus estimate of $148.8 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2026 revenue of $660-680 million, versus the consensus of $643.3 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.